15
CENOVAPHARMA PARTNER OF CHOICE

Cenovapharma Presentation Eng

Embed Size (px)

Citation preview

Page 1: Cenovapharma Presentation Eng

CENOVAPHARMA

PARTNER OF CHOICE

Page 2: Cenovapharma Presentation Eng

About Cenovapharma

Our Capabilities

Our Products

Cenovapharma Team

Current Sales and Force Size & Structure

Contact Us

CONTENT

Page 3: Cenovapharma Presentation Eng

Cenovapharma specializes in providing innovative and generic healthcare products to the Middle East, Africa, Turkey and the Caspian Regions. Cenovapharma'sfocused sales and marketing expertise coupled with in depth know-how provides biotechnology and pharmaceutical companies with a local partner to commercialize cutting-edge therapeutic products.

Cenovapharma focuses on the licensing and commercialization of high-value products such as diabetes, cardiovascular, ophthalmic and oncologic products-diseases with sharply rising regional incidence and prevalence.

Headquartered in Istanbul, Turkey, Cenovapharma was founded in 2010 by Faik Somer, an individual who has 22 years of experience in pharmaceutical industry .Another major partner of Cenovapharma is the Polish pharmaceutical company, Polpharma. With a history of 75 years, and offices in more than 15 major marketsand 2600 employees, Polpharma brings global connections and expertise toCenovapharma.

Cenovapharma has established regulatory, finance, supply chain, medical affairs, business development and strong sales and marketing capabilities. This integrated strategy and regional focus makes Cenovapharma the "partner-of-choice" for US, European, and Asian biotech and pharmaceutical companies seeking access to the rapidly expanding markets of the Middle East, Africa, Turkey and Caspian Regions.

ABOUT CENOVAPHARMA

PARTNER OF CHOICE

Page 4: Cenovapharma Presentation Eng

OUR CAPABILITIESIstanbul-based management team with proven success and expertise in

Middle East, Africa, Turkey and Caspian Market Healthcare

Strong commercilization know-how in selected therapeutic areas

supported by strong relations with key opinion leaders and all relevant

stakeholders

Fully aligned with good business practices and corporate governance

Global company approach with local know-how and speed

Strong financial structure

Ease of access to key decision makers including government authorities,

ministry of health, financial systems,social security system, insurance

providers and manufacturers-distributors

Page 5: Cenovapharma Presentation Eng

CENOVAPHARMA PRODUCTS

Description & IndicationCardyn is an atorvastatin which treats hyperlipidemia.

BenefitsPrimary hypercholesterolemiaReduces total cholesterol in dyslipidemia patientsReduces LDL-cholesterolReduces triglyceridesIncrease HDL-C levels

Regulatory StatusApproved in Turkey.

License PartnerTRIPHARMA

Page 6: Cenovapharma Presentation Eng

CENOVAPHARMA PRODUCTS

Description & IndicationDiameprid is a glimeprid which treats Type 2 Diabetes

BenefitsControls blood glucose level

Regulatory StatusApproved in Turkey.

License Partner MECOM

Page 7: Cenovapharma Presentation Eng

CENOVAPHARMA PRODUCTS

Description & IndicationGlynose is an acarbose which treats Type 2 Diabetes.

BenefitsReduces blood glucose level

Regulatory StatusApproved in Turkey.

License Partner

Page 8: Cenovapharma Presentation Eng

GLOKOPROST (latanoprost ophthalmic) Solution 0.005% (50 µg/mL)

Description & IndicationGLOKOPROST Sterile Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

BenefitsReduces intraocular pressure.

Regulatory StatusApproved in Turkey.

License Partner

CENOVAPHARMA PRODUCTS

Page 9: Cenovapharma Presentation Eng

TİDOMİX (dorzolamid HCl - timolol maleat) Solution 2% dorzolamid HCl, 0.5% timolol maleat

IndicationTİDOMİX is indicated for the reduction of elevated intraocular pressure in patients withopen-angle glaucoma, ocular hypertension, pseudoexfoliative or other secondary open-angleglaucoma where combination therapy is appropriate.

BenefitsReduces intraocular pressure.

Regulatory StatusApproved in Turkey.

License Partner

CENOVAPHARMA PRODUCTS

Page 10: Cenovapharma Presentation Eng

ACTOSDescription:Each tablet includes pioglitazone HCI equalivent to 15 mg pioglitazone.

Indication :Actos is a pioglitazone which treats Type 2 diabetes mellitus

Regulatory StatusApproved in Turkey.

License Partner

CENOVAPHARMA PRODUCTS

Page 11: Cenovapharma Presentation Eng

CENOVAPHARMA TEAM

Faik SOMERFounder, Chairman of the Board and Chief Executive Officer

Faik Somer founded Cenovapharma in 2010 shortly after leaving MSD. Mr. Somer began his management career in pharmaceutical industry over 22 years ago at FAKO, Pharmaceutical Leading Company in in-licensing andgenerics.

He established Merck Sharp Dohme license-business from base zero to15 million dollars in 3 years time. He managed the process of buying backthe business from the licensee and established MSD as a full-fledgeorganization in the Turkish Market through launching full portfolio of thecompany.

He developed the business as the managing director to 200 million dollars, a 500 people company in 9 years time. His proven success resulted in expandedresponsibilities in the title of Vice President managing Central Eastern Europe, CentralAsian Region grew the business from 300 million dollars to 700 milllion dollars in 5 years.

In his last role in MSD, Mr. Somer served as the President of Central Eastern Europe,Central Asia and Middle East, Africa Region; so-called “the emerging markets” managing more than 110 Countries. Again Mr. Somer rose to the task, growing the business from 700 million dollars to 2 billion dollars in 3 years time.

Page 12: Cenovapharma Presentation Eng

CENOVAPHARMA TEAM

Selim GİRAYCo Founder ,Managing PartnerSelim Giray started his career as a sales representative in 1999. After 2 years of experience in sales, in 2001 he decided to continue his career in pharmaceutical industry with Roche as a brand manager for OTC products. Shortlyafter, Mr. Giray joined Merck Sharp Dohme in 2004 as a brand manager for CV products, and successfully launchedEzetimibe and Ezetimibe/Simvastatin, leading the products to become most successful launches in Europe. He thenpromoted to become Regional Marketing Manager for Vaccines for the Middle East and Eastern Europe Region in 2006. Mr. Giray, became a member of board in MSD Turkey in 2008, in charge of all ethical drug sales of thecompany. Mr. Giray was in charge of a 300 person staff and 200 million dollars sales.Beside his successful career in the pharmaceutical industry, he created and led the first industry-academiapartnership program in Turkey- a 52 week “Pharmaceutical Industry Brand Manager Certification Program“ in cooperation with Bilgi University.

Aslan ASLANAĞIChief Financial OfficerAslan Aslanağı began his career in banking sector as a management trainee in 1998 at Iktisat Bank. Shortly after, he joined MSD Finance Department. Mr. Aslanağı became a manager in MSD with the responsibilities of planning, treasury and pricing. Due to his proven success in finance and business orientation,he was appointed as a projectrealization officer undertaking sales and marketing. He played a key role in establishing new commercial model in MSD, based on changing needs of industry capatilizing opportunities to the benefit of the company. After the mergeof SP and MSD he was again assigned to a key role as the leader of the integration team. In 2010, he joinedCenovapharma as CFO, establishing financial structure as well as other support departments. Mr. Aslanağı also holdssix sigma green belt certificate.

Page 13: Cenovapharma Presentation Eng

CENOVAPHARMA TEAM

Zeynep YAZGAN AKIALPHuman Resources DirectorZeynep Yazgan Akıalp started her career in pharmaceutical industry in 1998 with Roche as a Brand Manager. In 2000, she joined MSD Turkey organization, responsible for ARB franchise, one of the highest contributing products in company portfolio at the time. She played a key role in the success of the ARB franchise's expansion throughsuccessful launches of new forms and key studies.ARBbecome the market leader during her leadership as the SeniorBrand Manager forARBfranchise. She also led the Regional Marketing Team for CEE (Central Eastern Europe) contributing to the regional marketing strategies as well as ensuring successful launches in other countries in theregion. In 2006, she decided to broaden her contribution to the company through undertaking a strategic role in HR. Her business background combined with “strategic partnership” understanding she embraced for HR, created a strong value and input for the company. In her role in HR, she focused on strategic areas such as - successionplanning, strategic recruitment, performance management, and leadership. She has re-established the HR organization inline with “Business Partner Model,” positioning HR as strategic partner for the business. Through thisrevitalization of the department and understanding the needs of the business, she was able to successfully lead a major restructuring within the company supporting the management vision and goals. As the HR lead for theorganization she was a board member as well as a member of the CEEMEA HR leadership team. Mrs. Akialp joinedCenovapharma in 2010 responsible for establishing the organization based on strategy, as well as establishing key HR processes.

Page 14: Cenovapharma Presentation Eng

SALES FORCE SIZE & STRUCTURETargeted Specialized fields for;

- Cardiovasculer- Diabetes- Ophthalmology

Coverage- 67 Cities in Turkey- 7 regions

10 Regional Managers & 100 Region Sales Representatives

Page 15: Cenovapharma Presentation Eng

CONTACT US

Corporate address:

Cenova Sağlık Ürünleri San. ve Tic. A.Ş

Eski Büyükdere Asfaltı No: 17-5 Güney Plaza Kat:4

34398 Maslak - İSTANBUL

Contact Person:Faik SOMER, Founder, CEOSelim GİRAY, Co Founder, Managing Partner

Office:+90 (212) 285 04 04

Fax number:+90 (212) 285 17 17

Email address:[email protected]@cenova.com